← Back to patent-cliff list
Cetirizine Hydrochloride Injection(Shandong Kexin Huiyi Pharma)
Tier C — Watch / tradeCetirizine Hydrochloride Injection(Shandong Kexin Huiyi Pharma)
-
Originator
2024
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：HRH1
Indications (approved)：Urticaria
Regional status
US
-
EU
-
China
Approved
2024-06-28
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Cetirizine Hydrochloride Injection(Shandong Kexin Huiyi Pharma)?
Approved indications include: Urticaria.
When does the Cetirizine Hydrochloride Injection(Shandong Kexin Huiyi Pharma) patent expire?
No public expiry year is available for Cetirizine Hydrochloride Injection(Shandong Kexin Huiyi Pharma) yet; this page updates once verified.
How do I get a quote for Cetirizine Hydrochloride Injection(Shandong Kexin Huiyi Pharma) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27